AstraZeneca

AstraZeneca halted its Phase 3 coronavirus vaccine trial earlier this week following a severe reaction that may or may not have been induced by the vaccine. CEO Pascal Soriot addressed the matter in a private call with investors, explaining that a woman in the UK who received the vaccine candidate developed neurological issues. Her condition …

AstraZeneca confirmed that the Oxford vaccine’s Phase 3 trial was paused as it investigates the matter to determine what caused a serious adverse reaction in a volunteer in the UK. A report says a patient developed a condition called transverse myelitis, an inflammatory syndrome that affects the spinal cord. AstraZeneca has not confirmed the diagnosis, …

The coronavirus vaccine update we’ve been waiting for is finally here, as Oxford published the research for the Phase 1/2 clinical trial of its experimental drug. As previously detailed, the drug induces a dual immune response in volunteers that includes the production of neutralizing antibodies that bind to the spike protein of the virus and …

Coronavirus vaccine trials have hit a serious snag, as there aren’t enough COVID-19 patients in the communities where volunteers might reside. If not enough people get sick, researchers can’t assess the effectiveness of the vaccine candidate. AstraZeneca, which will produce the promising Oxford vaccine, confirmed that it’s considering challenge trials where subjects are exposed to …

One of the coronavirus vaccine candidates that has shown encouraging results is the one being developed at Oxford, which could be ready for emergency use this September. However, researchers are running into a potential issue with testing, as there might not be enough COVID-19 cases in the UK to actually see if the vaccine works …